Michael Dean

Dr. Michael Dean

National Cancer Institute, Bethesda, Maryland, USA
orcid

Research Focus & Metrics

Academic Career Length

47Years (1980-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2003 in Cell
Verified
Journal Article
Closed access
MEMichael F. Egan
Michael F. Egan
MKMasami Kojima
Masami Kojima
JCJoseph H. Callicott
Joseph H. Callicott
TGTerry E. Goldberg
Terry E. Goldberg
BKBhaskar S. Kolachana
Bhaskar S. Kolachana
DWDaniel R. Weinberger
Daniel R. Weinberger

1 April 2005 in Nature Reviews Cancer
Verified
Journal Article
Closed access
Michael DeanMichael Dean
Michael Dean
TFTito Fojo
Tito Fojo
SBSusan Bates
Susan Bates

8 September 1989 in Science
Verified
Journal Article
Closed access
PDF file
JRJohanna M. Rommens
Johanna M. Rommens
MIMichael C. Iannuzzi
Michael C. Iannuzzi
BKBat-Sheva Kerem
Bat-Sheva Kerem
MDMitchell L. Drumm
Mitchell L. Drumm
GMGeorg Melmer
Georg Melmer
EAEt Al.
Et Al.
An understanding of the basic defect in the inherited disorder cystic fibrosis requires cloning of the cystic fibrosis gene and definition of its protein product. In the absence of direct functional information, chromosomal map position is a guide for locating the gene. Chromosome walking and jumping and complementary DNA hybridization were used to isolate DNA sequences, encompassing more than 500,000 base pairs, from the cystic fibrosis region on the long arm of human chromosome 7. Several transcribed sequences and conserved segments were identified in this cloned region. One of these corresponds to the cystic fibrosis gene and spans approximately 250,000 base pairs of genomic DNA.

28 May 1993 in Science
Verified
Journal Article
Closed access
PDF file
FLFarida Latif
Farida Latif
KTKalman Tory
Kalman Tory
JGJames Gnarra
James Gnarra
MYMasahiro Yao
Masahiro Yao
FDFuh-Mei Duh
Fuh-Mei Duh
AEAl. Et
Al. Et
A gene discovered by positional cloning has been identified as the von Hippel-Lindau (VHL) disease tumor suppressor gene. A restriction fragment encompassing the gene showed rearrangements in 28 of 221 VHL kindreds. Eighteen of these rearrangements were due to deletions in the candidate gene, including three large nonoverlapping deletions. Intragenic mutations were detected in cell lines derived from VHL patients and from sporadic renal cell carcinomas. The VHL gene is evolutionarily conserved and encodes two widely expressed transcripts of approximately 6 and 6.5 kilobases. The partial sequence of the inferred gene product shows no homology to other proteins, except for an acidic repeat domain found in the procyclic surface membrane glycoprotein of Trypanosoma brucei .

27 September 1996 in Science
Verified
Journal Article
Open access
PDF file
Michael DeanMichael Dean
Michael Dean
MCMary Carrington
Mary Carrington
CWCheryl Winkler
Cheryl Winkler
GHGavin A. Huttley
Gavin A. Huttley
MSMichael W. Smith
Michael W. Smith
SOStephen J. O'Brien
Stephen J. O'Brien
The chemokine receptor 5 (CKR5) protein serves as a secondary receptor on CD4 + T lymphocytes for certain strains of human immunodeficiency virus-type 1 (HIV-1). The CKR5 structural gene was mapped to human chromosome 3p21, and a 32-base pair deletion allele ( CKR5Δ32 ) was identified that is present at a frequency of ∼0.10 in the Caucasian population of the United States. An examination of 1955 patients included among six well-characterized acquired immunodeficiency syndrome (AIDS) cohort studies revealed that 17 deletion homozygotes occurred exclusively among 612 exposed HIV-1 antibody-negative individuals (2.8 percent) and not at all in 1343 HIV-1-infected individuals. The frequency of CKR5 deletion heterozygotes was significantly elevated in groups of individuals that had survived HIV-1 infection for more than 10 years, and, in some risk groups, twice as frequent as their occurrence in rapid progressors to AIDS. Survival analysis clearly shows that disease progression is slower in CKR5 deletion heterozygotes than in individuals homozygous for the normal CKR5 gene. The CKR5Δ32 deletion may act as a recessive restriction gene against HIV-1 infection and may exert a dominant phenotype of delaying progression to AIDS among infected individuals.

3 May 2005 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
GHGregory S. Hageman
Gregory S. Hageman
DADon H. Anderson
Don H. Anderson
LJLincoln V. Johnson
Lincoln V. Johnson
LHLisa S. Hancox
Lisa S. Hancox
ATAndrew J. Taiber
Andrew J. Taiber
RARando Allikmets
Rando Allikmets
Age-related macular degeneration (AMD) is the most frequent cause of irreversible blindness in the elderly in developed countries. Our previous studies implicated activation of complement in the formation of drusen, the hallmark lesion of AMD. Here, we show that factor H (HF1), the major inhibitor of the alternative complement pathway, accumulates within drusen and is synthesized by the retinal pigmented epithelium. Because previous linkage analyses identified chromosome 1q25-32, which harbors the factor H gene ( HF1 / CFH ), as an AMD susceptibility locus, we analyzed HF1 for genetic variation in two independent cohorts comprised of ≈900 AMD cases and 400 matched controls. We found association of eight common HF1 SNPs with AMD; two common missense variants exhibit highly significant associations (I62V, χ 2 = 26.1 and P = 3.2 × 10 -7 and Y402H, χ 2 = 54.4 and P = 1.6 × 10 -13 ). Haplotype analysis reveals that multiple HF1 variants confer elevated or reduced risk of AMD. One common at-risk haplotype is present at a frequency of 50% in AMD cases and 29% in controls [odds ratio (OR) = 2.46, 95% confidence interval (1.95-3.11)]. Homozygotes for this haplotype account for 24% of cases and 8% of controls [OR = 3.51, 95% confidence interval (2.13-5.78)]. Several protective haplotypes are also identified (OR = 0.44-0.55), further implicating HF1 function in the pathogenetic mechanisms underlying AMD. We propose that genetic variation in a regulator of the alternative complement pathway, when combined with a triggering event, such as infection, underlie a major proportion of AMD in the human population.